Table 3 Performance measures of seven-gene Heterogeneous Mixture Discriminant Analysis (MDAhet) classifier
| Â | Training set | Â | Â | Test | Sets | Â | Â |
|---|---|---|---|---|---|---|---|
Cohort | NKI2+EMC+NCH | UPP | JRH-2 | CAL | Kreike | UNC248 | Loi |
Cohort size | 186 | 34 | 24 | 46 | 97 | 85 | 40 |
Annotated | 183 | 31 | 24 | 46 | 71 | 80 | 34 |
Good prognosis (%) | 59 | 81 | 75 | 67 | 76 | 74 | 76 |
Poor prognosis (%) | 41 | 19 | 25 | 33 | 24 | 26 | 24 |
Chemotherapy (%) | 0 | 0 | 0 | 67 | 0 | 66 | 0 |
MDA | Â | Â | Â | Â | Â | Â | Â |
NPV (%) | 74 | 92 | 93 | 69 | 83 | 74 | 100 |
PPV (%) | 55 | 28 | 56 | 35 | 29 | 27 | 40 |
SE (%) | 69 | 83 | 83 | 53 | 71 | 38 | 100 |
SP (%) | 61 | 48 | 78 | 52 | 44 | 63 | 54 |
MDAhet | Â | Â | Â | Â | Â | Â | Â |
NPV (%) | 80 | 100 | 100 | 100 | 85 | 92 | 100 |
PPV (%) | 51 | 30 | 37 | 45 | 29 | 36 | 35 |
SE (%) | 84 | 100 | 100 | 100 | 76 | 90 | 100 |
SP (%) | 44 | 44 | 44 | 42 | 41 | 42 | 42 |
NPV at 4 years (%) | 83 | 100 | 100 | 100 | 88 | 93 | 100 |
PPV at 4 years (%) | 42 | 24 | 33 | 35 | 25 | 45 | 35 |
SE at 4 years (%) | 83 | 100 | 100 | 100 | 79 | 88 | 100 |
SP at 4 years (%) | 44 | 42 | 43 | 37 | 40 | 45 | 43 |
LN | Â | Â | Â | Â | Â | Â | Â |
NPV (%) | 61 | 84 | NA | 85 | NA | 85 | 76 |
PPV (%) | 50 | 30 | NA | 46 | NA | 37 | 0a |
SE (%) | 27 | 50 | NA | 80 | NA | 71 | 0a |
SP (%) | 81 | 70 | NA | 55 | NA | 58 | 100a |
NPV at 4 years (%) | 67 | 88 | NA | 90 | NA | 82 | 77 |
PPV at 4 years (%) | 39 | 37 | NA | 38 | NA | 47 | 0a |
SE at 4 years (%) | 25 | 84 | NA | 85 | NA | 69 | 0a |
SP at 4 years (%) | 80 | 74 | NA | 53 | NA | 60 | 100a |